435 related articles for article (PubMed ID: 7556414)
1. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.
Maurice DH; Haslam RJ
Mol Pharmacol; 1990 May; 37(5):671-81. PubMed ID: 2160060
[TBL] [Abstract][Full Text] [Related]
3. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
[TBL] [Abstract][Full Text] [Related]
4. Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo.
Spiecker M; Darius H; Meyer J
Thromb Res; 1993 Jun; 70(5):405-15. PubMed ID: 7690993
[TBL] [Abstract][Full Text] [Related]
5. Effects of nitrovasodilators on platelet cyclic nucleotide levels in rabbit blood; role for cyclic AMP in synergistic inhibition of platelet function by SIN-1 and prostaglandin E1.
Bowen R; Haslam RJ
J Cardiovasc Pharmacol; 1991 Mar; 17(3):424-33. PubMed ID: 1711604
[TBL] [Abstract][Full Text] [Related]
6. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
[TBL] [Abstract][Full Text] [Related]
7. Synergistic phosphorylation of platelet rap1B by SIN-1 and iloprost.
Grünberg B; Negrescu E; Siess W
Eur J Pharmacol; 1995 Feb; 288(3):329-33. PubMed ID: 7539769
[TBL] [Abstract][Full Text] [Related]
8. Synergistic platelet inhibitory effect of the phosphodiesterase inhibitor piroximone and iloprost.
Buerke M; Dieterich HA; Meyer J; Darius H
Agents Actions Suppl; 1992; 37():71-7. PubMed ID: 1378692
[TBL] [Abstract][Full Text] [Related]
9. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
Haslam RJ; Davidson MM; Desjardins JV
Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
[TBL] [Abstract][Full Text] [Related]
11. YC-1, a novel activator of platelet guanylate cyclase.
Ko FN; Wu CC; Kuo SC; Lee FY; Teng CM
Blood; 1994 Dec; 84(12):4226-33. PubMed ID: 7527671
[TBL] [Abstract][Full Text] [Related]
12. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity.
Gerzer R; Karrenbrock B; Siess W; Heim JM
Thromb Res; 1988 Oct; 52(1):11-21. PubMed ID: 2904706
[TBL] [Abstract][Full Text] [Related]
13. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
14. Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors.
Nolte C; Eigenthaler M; Horstrup K; Hönig-Liedl P; Walter U
Biochem Pharmacol; 1994 Oct; 48(8):1569-75. PubMed ID: 7980622
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of prostaglandin E1-induced activation of adenylate cyclase in human blood platelet membrane.
Kahn NN; Sinha AK
Biochim Biophys Acta; 1988 Oct; 972(1):45-53. PubMed ID: 2902882
[TBL] [Abstract][Full Text] [Related]
16. Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
Bult H; Fret HR; Herman AG
J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S120-3. PubMed ID: 2484689
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation.
Méry PF; Pavoine C; Belhassen L; Pecker F; Fischmeister R
J Biol Chem; 1993 Dec; 268(35):26286-95. PubMed ID: 7902837
[TBL] [Abstract][Full Text] [Related]
18. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors.
Seiler S; Brassard CL; Federici ME
Prostaglandins; 1990 Aug; 40(2):119-30. PubMed ID: 2171039
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins.
Radziszewski W; Chopra M; Zembowicz A; Gryglewski R; Ignarro LJ; Chaudhuri G
Int J Cardiol; 1995 Oct; 51(3):211-20. PubMed ID: 8586470
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
